ASX-listed breast cancer diagnostic company Volpara Health Technologies has released promising half-year results, with millions in revenue growth despite massive disruption to cancer diagnostics with Covid-19.
However, growing losses appeared to spook investors, and the company’s share
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
